Posted by Michael Wonder on 10 Nov 2022
Seagen announces US FDA approval of new indication for Adcetris (brentuximab vedotin) for children with previously untreated high risk Hodgkin's lymphoma
10 November 2022 - Approval based on Phase 3 clinical trial that demonstrated a 59% reduction in risk of disease progression or relapse, second malignancy or death versus standard of care.
Seagen today announced that the US FDA has approved Adcetris (brentuximab vedotin) for the treatment of paediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
